CN101559196B - Medicament for treating the hyperplasia of mammary glands and preparation method thereof - Google Patents
Medicament for treating the hyperplasia of mammary glands and preparation method thereof Download PDFInfo
- Publication number
- CN101559196B CN101559196B CN2008100179980A CN200810017998A CN101559196B CN 101559196 B CN101559196 B CN 101559196B CN 2008100179980 A CN2008100179980 A CN 2008100179980A CN 200810017998 A CN200810017998 A CN 200810017998A CN 101559196 B CN101559196 B CN 101559196B
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- medicine
- herbaceous peony
- breast
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 66
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 206010020718 hyperplasia Diseases 0.000 title abstract description 14
- 210000005075 mammary gland Anatomy 0.000 title abstract description 13
- 238000004519 manufacturing process Methods 0.000 claims abstract description 4
- 239000002994 raw material Substances 0.000 claims abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 36
- 241001550206 Colla Species 0.000 claims description 15
- 241000209020 Cornus Species 0.000 claims description 15
- 241000195474 Sargassum Species 0.000 claims description 11
- -1 filters Substances 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 239000000706 filtrate Substances 0.000 claims description 9
- 239000000796 flavoring agent Substances 0.000 claims description 9
- 235000019634 flavors Nutrition 0.000 claims description 9
- 238000004064 recycling Methods 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 5
- 235000014375 Curcuma Nutrition 0.000 claims description 4
- 241001530126 Scrophularia Species 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 230000006837 decompression Effects 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 239000012567 medical material Substances 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- 230000003068 static effect Effects 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 241000407170 Curcuma Species 0.000 claims 2
- 235000006484 Paeonia officinalis Nutrition 0.000 abstract description 69
- 230000000694 effects Effects 0.000 abstract description 11
- 241001465754 Metazoa Species 0.000 abstract description 9
- 238000000034 method Methods 0.000 abstract description 6
- 238000012360 testing method Methods 0.000 abstract description 5
- 231100000331 toxic Toxicity 0.000 abstract description 4
- 230000002588 toxic effect Effects 0.000 abstract description 4
- 244000179560 Prunella vulgaris Species 0.000 abstract description 3
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- 241001474374 Blennius Species 0.000 abstract 1
- 241000202726 Bupleurum Species 0.000 abstract 1
- 241000675108 Citrus tangerina Species 0.000 abstract 1
- 244000163122 Curcuma domestica Species 0.000 abstract 1
- 241000935235 Fritillaria meleagris Species 0.000 abstract 1
- 244000170916 Paeonia officinalis Species 0.000 abstract 1
- 235000010674 Prunella vulgaris Nutrition 0.000 abstract 1
- 210000003056 antler Anatomy 0.000 abstract 1
- 235000003373 curcuma longa Nutrition 0.000 abstract 1
- 238000002481 ethanol extraction Methods 0.000 abstract 1
- 239000003292 glue Substances 0.000 abstract 1
- 238000003809 water extraction Methods 0.000 abstract 1
- 210000000481 breast Anatomy 0.000 description 78
- 239000002775 capsule Substances 0.000 description 70
- 241000736199 Paeonia Species 0.000 description 68
- 241000700159 Rattus Species 0.000 description 40
- 241000699670 Mus sp. Species 0.000 description 32
- 239000008280 blood Substances 0.000 description 26
- 210000004369 blood Anatomy 0.000 description 24
- 229940079593 drug Drugs 0.000 description 22
- 241000699666 Mus <mouse, genus> Species 0.000 description 20
- 208000002193 Pain Diseases 0.000 description 18
- 230000036407 pain Effects 0.000 description 18
- 208000007536 Thrombosis Diseases 0.000 description 16
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 15
- 238000002347 injection Methods 0.000 description 13
- 239000007924 injection Substances 0.000 description 13
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 12
- 206010042674 Swelling Diseases 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 230000008961 swelling Effects 0.000 description 12
- 230000003203 everyday effect Effects 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 230000001629 suppression Effects 0.000 description 11
- 206010020880 Hypertrophy Diseases 0.000 description 8
- 238000005469 granulation Methods 0.000 description 8
- 230000003179 granulation Effects 0.000 description 8
- 206010053567 Coagulopathies Diseases 0.000 description 7
- 206010030113 Oedema Diseases 0.000 description 7
- 230000035602 clotting Effects 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 239000000186 progesterone Substances 0.000 description 7
- 229960003387 progesterone Drugs 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- UYIFTLBWAOGQBI-BZDYCCQFSA-N Benzhormovarine Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4O)C)CC2=CC=3OC(=O)C1=CC=CC=C1 UYIFTLBWAOGQBI-BZDYCCQFSA-N 0.000 description 6
- 240000001624 Espostoa lanata Species 0.000 description 6
- 235000009161 Espostoa lanata Nutrition 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 229950002007 estradiol benzoate Drugs 0.000 description 6
- 210000002683 foot Anatomy 0.000 description 6
- 230000002496 gastric effect Effects 0.000 description 6
- 238000001802 infusion Methods 0.000 description 6
- 206010006298 Breast pain Diseases 0.000 description 5
- 206010062717 Increased upper airway secretion Diseases 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 208000006662 Mastodynia Diseases 0.000 description 5
- 230000036592 analgesia Effects 0.000 description 5
- 230000004856 capillary permeability Effects 0.000 description 5
- 229920001525 carrageenan Polymers 0.000 description 5
- 235000010418 carrageenan Nutrition 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 208000026435 phlegm Diseases 0.000 description 5
- 206010018691 Granuloma Diseases 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 229940113118 carrageenan Drugs 0.000 description 4
- 239000000679 carrageenan Substances 0.000 description 4
- 230000004087 circulation Effects 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 206010007247 Carbuncle Diseases 0.000 description 3
- 241000721047 Danaus plexippus Species 0.000 description 3
- 208000000571 Fibrocystic breast disease Diseases 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 3
- 229960002327 chloral hydrate Drugs 0.000 description 3
- 230000000994 depressogenic effect Effects 0.000 description 3
- 230000002124 endocrine Effects 0.000 description 3
- 239000003172 expectorant agent Substances 0.000 description 3
- 230000003419 expectorant effect Effects 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 201000007227 lymph node tuberculosis Diseases 0.000 description 3
- 230000003285 pharmacodynamic effect Effects 0.000 description 3
- 208000037920 primary disease Diseases 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
- 240000006409 Acacia auriculiformis Species 0.000 description 2
- 244000164439 Curcuma angustifolia Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 208000008771 Lymphadenopathy Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 208000013228 adenopathy Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 208000030270 breast disease Diseases 0.000 description 2
- 208000011803 breast fibrocystic disease Diseases 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 210000005069 ears Anatomy 0.000 description 2
- 229960005309 estradiol Drugs 0.000 description 2
- 229930182833 estradiol Natural products 0.000 description 2
- 230000001076 estrogenic effect Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 210000002445 nipple Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000000583 progesterone congener Substances 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- ATADHKWKHYVBTJ-FVGYRXGTSA-N (R)-adrenaline hydrochloride Chemical compound [H+].[Cl-].CNC[C@H](O)C1=CC=C(O)C(O)=C1 ATADHKWKHYVBTJ-FVGYRXGTSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N Adrenalin Natural products CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- UCTWMZQNUQWSLP-UHFFFAOYSA-N Adrenaline Natural products CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 206010016228 Fasciitis Diseases 0.000 description 1
- 206010061245 Internal injury Diseases 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 208000000114 Pain Threshold Diseases 0.000 description 1
- 240000002834 Paulownia tomentosa Species 0.000 description 1
- 235000010678 Paulownia tomentosa Nutrition 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010043458 Thirst Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 229940102884 adrenalin Drugs 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 208000026555 breast adenosis Diseases 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 230000035568 catharsis Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 108010084652 homeobox protein PITX1 Proteins 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 238000000643 oven drying Methods 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 230000037040 pain threshold Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229940011964 pentobarbital sodium 30 mg Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- ZRHANBBTXQZFSP-UHFFFAOYSA-M potassium;4-amino-3,5,6-trichloropyridine-2-carboxylate Chemical compound [K+].NC1=C(Cl)C(Cl)=NC(C([O-])=O)=C1Cl ZRHANBBTXQZFSP-UHFFFAOYSA-M 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000757 progestagenic effect Effects 0.000 description 1
- 230000006259 progesterone secretion Effects 0.000 description 1
- 230000035752 proliferative phase Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a medicament for treating the hyperplasia of mammary glands, belonging to the technical field of medicine manufacture. The invention also discloses a preparation method. The medicament comprises the following raw material components: 150 to 190 parts of bupleurum, 150 to 190 parts of curcuma longa, 150 to 190 parts of red peony roots, 235 to 275 parts of prunella vulgaris, 150 to 190 parts of rhizoma cyperi, 75 to 95 parts of antler glue, 150 to 190 parts of tangerine seeds, 235 to 275 parts of radix scrophulariae, 75 to 95 parts of fritillary bulb and 150 to 190 parts of seaweed, and is prepared by an ethanol extraction method and a water extraction method. Proved by animal tests, the medicament for treating the hyperplasia of mammary glands has obvious therapeuticaction on the hyperplasia of mammary glands, little toxic side effect, high cure rate and low recurernce rate.
Description
One, technical field
The present invention relates to a kind of medicine, specifically a kind of medicine for the treatment of cyclomastopathy belongs to medicine manufacture technology field, comprises preparation method.
Two, background technology
Cyclomastopathy is with the periodicity distending pain of the breast, and lump in breast is the commonly encountered diseases of the young women of clinical characters, good sending out in 25～50 years old the women of child-bearing age, and maiden and man also have generation.Be a kind of non-inflammation disease of breast portion, in Chinese medicine, belong to " nodules of the breast " category.Claim " milk spleen ", " infantile dyspepsia " again.Motherland's medical science is thought the liver failing to maintain the normal flow of QI, Chong and Ren channel disorder and to cause QI-blood circulation not smooth, qi depression to blood stasis, the expectorant poly-nodules of the breast that forms that condenses." Yangke Xinde Ji, Experience Gained in Treating External Diseases " cloud: " nodule in the breast shape such as ball ovum, pain is not had a fever, and color of the leather is constant, it examines the growth and decline with susceptible to anger, this nodules of the breast ".Modern medicine thinks that the pathogenic factor of primary disease is an endocrine regulation, mainly is that estrogen secretion is too much, and progestogen, Progesterone secretion relative deficiency cause.Sickness rate is domestic to be reported as about 10%, and existing prevalence 38.8%～49.3%, and the danger of generation breast carcinoma is apparently higher than general women.Cyclomastopathy is commonly encountered diseases, the frequently-occurring disease of young women, and at present Western medicine is advocated with hormones, vitamin medicaments treatment more, but curative effect still do not have definitely, and side effect is big, treat not thorough, the easy recurrence.So research is a kind of efficiently, the research utmost point of the medicine treatment by Chinese herbs primary disease of low toxicity has realistic meaning and bright prospects.
Cyclomastopathy title clinically is a lot, and as breast disease, fibrocystic disease of breast, adenosis of breast, cyclomastopathy etc., world health organisation recommendations is called mammary dysplasia disease, and the most scholars of China still commonly use the title of cyclomastopathy.Along with improving constantly of living standard, this disease sickness rate presents the rising situation.Present national average statistics is 50%, and some areas have reached 60%～70%.Most scholars think that this disease is relevant with hypothalamic-pituitary-ovarian-mammary gland endocrine axis disorder, be the result of multiple endocrine hormone imbalance, wherein estrogenic/progestogenic out of proportion make mammary gland under estrogenic stimulation the essence hypertrophy excessively and subinvolution be one of most important reason.
Cyclomastopathy is a main clinical manifestation with two big primary symptoms such as mastalgia and lump in breasies.The pain of early lesion (being mastalgia and cyclomastopathy) is very obvious, and along with further developing of the state of an illness, then pain relief and lump occur to the adenopathy hypertrophy.Develop into cystic hyperplasia, then pain almost disappears and lump shows especially.Therefore, we are divided into pain type, lump type and middle type by its clinical manifestation with hypertrophy.Three types are pressed lesion degree by light arrangement to weight, are followed successively by pain type → middle type → lump type.In pathological change, be equivalent to mastalgia or cyclomastopathy phase respectively, adenopathy proliferative phase and cystic hyperplasia phase.The obvious degree of three type lumps increases successively, and is close gradually with getting in touch of tumor, but pain degree alleviates successively.Mastalgia is a kind of performance of early lesion to a certain extent, and from cyclomastopathy and relationship with canceration, it is actually a kind of signal for "speed OK", and promptly the obvious more person of pain is far away more from canceration.Lump is that cyclomastopathy is main, the sign of most critical, mostly is lamellar or block tuberosity, and the former fills the air and soft, and the latter limits to and tough reality slightly, and is hard and have the profile person answers highly vigilant of to its matter of later stage.
Three, summary of the invention
The purpose of this invention is to provide a kind of pure Chinese medicine medicine for the treatment of cyclomastopathy, this medicine embodies the characteristics of traditional Chinese medical science compatibility theory, and mastalgia and lump in breast two big primary symptoms at cyclomastopathy are conceived to eliminate lump, thereby a kind of new therapeutic scheme is provided.
Primary disease is mainly because of feelings will internal injury, and the damp and hot expectorant of stagnation of liver-QI coagulates, due to qi stagnation blood stasis or the Chong and Ren channel disorder.Monarch drug is selected Radix Bupleuri for use in the side, and property is opened and loose and catharsis is the key medicine of dispersing the stagnated live-QI to relieve the stagnation of QI.Radix Curcumae promoting QI circulation for relieving depression, removing heat from blood removing blood stasis with potent drugs, acrid in the mouth are from sun, and main row looses, and goes into edema caused by disorder of QI, can separate the invisible stagnation of QI; Bitter in the mouth is from the moon, and main falling rushed down, and goes into blood system, thus can break tangible blood stasis, for stagnation of liver-QI is not understood QI and blood stasis, the principal agent of distending pain of the breast." book on Chinese herbal medicine is equipped with medicine " carries Radix Curcumae: " circulation of qi promoting, resolving depression; Let out blood, removing blood stasis with potent drugs.Cool heat in the heart, the stagnation of liver-QI of loosing is controlled married woman's passages through which vital energy circulates and is driven in the wrong direction." monarch drug two flavors, a gas one blood, QI and blood is ruled together, promoting flow of QI and blood, resolving depression pain relieving.Ministerial drug is selected Radix Paeoniae Rubra for use, gets its flavor sour in taste acting on the liver, and relieving spasm to stop pain is gentle foster just dirty, stagnating in the promoting the circulation of blood.Spica Prunellae is apt to away scurry, and is longer than sensible meridians, energy hard masses softening and resolving, the detumescence of reducing phlegm.Shennong's Herbal meaning Spica Prunellae: " cure mainly cold and heat, scrofula, scrofula, head sore ， Po wei, the wart stagnation of QI that looses, swelling of the feet arthralgia chiefly caused by damp pathogen." Rhizoma Cyperi function depressed liver-energy dispersing and QI regulating, with Radix Bupleuri, Radix Curcumae matches, to help the merit of depressed liver-energy dispersing and QI regulating resolving depression.The Colla cornus cervi salty in the mouth is warm in nature, returns the Liver and kidney warp, energy temperature compensation Liver and kidney, benefiting essence-blood, ministerial drug four flavors, depressed liver-energy dispersing and QI regulating, hard masses softening and resolving.Adjuvant drug is selected the Semen Citri Reticulatae removing obstruction for relieving pain of regulating the flow of vital energy for use.The Radix Scrophulariae clearing away heat and cooling blood, the YIN nourishing detoxifcation." Mingyi Bielu " carries Radix Scrophulariae: " following water ends excessive thirst, and the neck that looses is nuclear, carbuncle down." Bulbus Fritillariae Thunbergii heat clearing away eliminating stagnation, preventing phlegm from forming and stopping coughing." book on Chinese herbal medicine is just " calls it: " fall mental disorder most, kind relieving stagnation is separated pyretic toxicity and is treated sore throat, scrofula, acute mastitis, carbuncle on the back, all carbuncle and ulcer toxic swellings ...." the Sargassum hardship is salty-cold, hard masses softening and resolving, expectorant diuretic.The same usefulness of adjuvant drug four flavor helps the merit of the monarch and his subjects' dissipating phlegm and resolving masses altogether.Colla cornus cervi is warming YANG system the moon in the cold and cool medicine of group, had both avoided medicine to cross cold and cool impairment of YIN, exchanges and dash the merit that plays using corrigent with blood.Full side's medication is the long memorial liver and qi altogether, transfers and dashes and blood, the merit of dissipating phlegm and resolving masses.
The present invention realizes by following scheme:
The consumption of drug component of the present invention also draws through various experimental summaries, and each amounts of components is for all having better curative effect in the following weight parts scope:
150～190 parts of Radix Bupleuri, 150～190 parts of Radix Curcumaes, 150～190 parts of Radix Paeoniae Rubra, 235～275 parts of Spica Prunellaes, 150～190 parts of Rhizoma Cyperis, 75～95 parts of Colla cornus cervis, 150～190 parts of Semen Citri Reticulataes, 235～275 parts of Radix Scrophulariaes, 75～95 parts of Bulbus Fritillariae Thunbergiis, 150～190 parts of Sargassums.
Be preferably:
170 parts of Radix Bupleuri, 170 parts of Radix Curcumaes, 170 parts of Radix Paeoniae Rubra, 255 parts of Spica Prunellaes, 170 parts of Rhizoma Cyperis, 85 parts of Colla cornus cervis, 170 parts of Semen Citri Reticulataes, 255 parts of Radix Scrophulariaes, 85 parts of Bulbus Fritillariae Thunbergiis, 170 parts of Sargassums.
Medicine of the present invention can adopt the conventional preparation method of Chinese medicine preparation to make any oral medicinal herb preparation.The preparation method of preferred medicine activity component of the present invention is as follows:
Above-mentioned ten flavors, Colla cornus cervi and Bulbus Fritillariae Thunbergii are ground into fine powder, and Radix Paeoniae Rubra is with 80% alcohol reflux 3 times, and each 1.0 hours, alcohol adding amount was 6 times, merge extractive liquid,, filtration, filtrate recycling ethanol also is evaporated to the thick paste of relative density 1.30～1.35 (80 ℃); Medicinal residues and Radix Bupleuri, Radix Curcumae, Spica Prunellae, Rhizoma Cyperi, Semen Citri Reticulatae, Radix Scrophulariae, Sargassum merge, adding 8 times of medical material water gagings decocts 3 times, each 1.5 hours, collecting decoction filtered, filtrate decompression is concentrated into the clear paste of relative density 1.10～1.15 (80 ℃), add ethanol and make determining alcohol reach 50%, fully stir static 24 hours, filter, filtrate recycling ethanol also is evaporated to the thick paste of relative density 1.30～1.35 (80 ℃); Thick paste and Radix Paeoniae Rubra alcohol extract merge, and add Colla cornus cervi and Bulbus Fritillariae Thunbergii fine powder, and 80 ℃ of drying under reduced pressure are ground into fine powder.
The active component of medicine of the present invention can add various conventional adjuvant required when preparing different dosage form, be prepared into any peroral dosage form commonly used as excipient, diluent, binding agent, disintegrating agent, lubricant etc. with the method for Chinese medicinal of routine, as pill, powder, granule, tablet, syrup, drop pill, capsule, fluid extract and extractum, oral liquid etc.
Good effect of the present invention is: component is few, have only ten flavor raw materials, method for production is simple, pure Chinese medicinal preparation by the pure Chinese medicine of ten flavors such as Radix Bupleuri, Radix Paeoniae Rubra processes through modern crafts according to the theory of Chinese medical science prescription, has liver-smoothing, qi-regulating, transfers and dash and functions such as blood, dissipating phlegm and resolving masses, be used for the treatment of gynaecopathias such as cyclomastopathy clinically, the cure rate height, relapse rate is low, and toxic and side effects is little.
Drug usage consumption of the present invention, oral dose calculated for 20.4 gram/days with the crude drug amount.
Effect experiment
Pharmacodynamic experiment is the result show: this medicine has obvious inhibitory action to the cyclomastopathy of cyclomastopathy rat; The rat paw edema that on Carrageenan causes has obvious inhibitory action, can obviously suppress the swelling of mice caused by dimethylbenzene xylene auricle inflammation, cause swelling of rat granulation and filter paper to cause the mice granulation hyperplasia that the obvious suppression effect is arranged to cotton balls, the mouse peritoneal capillary permeability that Dichlorodiphenyl Acetate causes strengthens obvious inhibitory action, illustrates that the present invention has tangible antiinflammatory action; Medicine of the present invention causes that to hot plate mice pain has significant analgesia role, and the mouse writhing increased frequency that Dichlorodiphenyl Acetate causes has the obvious suppression effect, illustrates that it has significant analgesia role.The present invention can obviously suppress rat vivo and vitro thrombosis, prolongs clotting time, illustrates that this medicine has tangible function of promoting blood circulation to disperse blood clots.And there is not tangible toxic reaction.
Below further set forth the beneficial effect of medicine of the present invention by animal experiment, these tests have comprised that the medicine bavin Chinese herbaceous peony breast that the present invention produced increases the pharmacodynamics test that capsule carries out.
Test material
Laboratory animal: wistar rat, body weight 170～230g female (each experimental animal body weight difference be no more than 50g), the quality certification number: SCXK-(Ji) 2003-0004; Kunming kind white mice, body weight 18～22g, female, the quality certification number: SCXK-(Ji) 2003-0004.All rats, white mice are all available from high-new medical experiment zooscopy center, Changchun.
Trial drug: bavin Chinese herbaceous peony breast increases capsule, and the Jilin Prov. Inst. of Chinese Medicine and Chinese Medical Science provides.Lot number: 040301, the patent medicine specification: the 0.4g/ grain is made into desired concn for gastric infusion with distilled water during experiment.RUKANG PIAN, Ankang Chia Tai Pharmaceutical Co., Ltd. provides.Lot number: 040102, the patent medicine specification: the 0.35g/ sheet is made into desired concn for gastric infusion with distilled water during experiment.Adrenalin hydrochloride (Adr) injection is produced by Tian Feng pharmaceutical factory, Shanghai, lot number: 940501; Chloral hydrate, Gaobeidian City, Hebei spring scenery chemical reagent work produces, lot number: 960908.
Instrument: BJ-8402 type hot plate dolorimeter, produce by Chinese Zhejiang; 752 type ultraviolet spectrophotometers are produced by Shanghai the 3rd analytical tool factory.
Test method and result
1, antiinflammatory action:
1.1, the influence of rat paw edema due to the on Carrageenan:
Get 50 of rats, be divided into 5 groups at random.The blank group; RUKANG PIAN 1.12g/kg dosed administration group; Bavin Chinese herbaceous peony breast increases capsule 1.12,0.56, three dosed administration groups of 0.28g/kg.Be administered once every day, successive administration five days.Injected 1% carrageenin 0.1ml/ down only in the right back toes aponeurosis (aponeuroses) of rat in 1 hour after the last administration.And in injecting the rat paw edema degree of surveying respectively in back 1,2,3,4,5,6,24 hour.With two back foot swelling differences as the swelling index.The results are shown in Table 1.
By table 1 result as seen, RUKANG PIAN and bavin Chinese herbaceous peony breast increase the rat paw edema that the capsule on Carrageenan causes the obvious suppression effect, and presents certain dose-effect relationship, and bavin Chinese herbaceous peony breast increased capsule 1.12g/kg effect sustainable 24 hours.
1.2, to the bullate influence of rat granuloma
With 50 of healthy rats, lumbar injection pentobarbital sodium 30mg/kg anesthesia, cut the long osculum of 1cm at groin place, the left and right sides of every Mus, autoclaving cotton balls (penicillin and streptomycin mixed liquor 0.2ml immersion with 20mg, 60 ℃ of oven dry) implant from incision subcutaneous, about each skin suture immediately.These rats are divided into 5 groups at random.The blank group; RUKANG PIAN 1.12g/kg dosed administration group; Bavin Chinese herbaceous peony breast increases capsule 1.12,0.56, three dosed administration groups of 0.28g/kg.Be administered once every day, successive administration 7 days.After the last administration 1 hour, open former otch, cotton balls is taken out together with connective tissue on every side, reject fatty tissue, put 70 ℃ of oven dry in the baking oven, weigh.With claim weight deduct the former weight of cotton balls and promptly get granuloma weight.The results are shown in Table 2.
By table 2 result as seen, RUKANG PIAN and bavin Chinese herbaceous peony breast increase capsule 1.12,0.56g/kg causes the swelling of rat granulation that the obvious suppression effect is arranged to cotton balls, and present certain dose-effect relationship.
1.3, xylol causes the inhibitory action of Mice Auricle inflammation swelling:
Get 60 mices, be divided into 5 groups at random.The blank group; RUKANG PIAN 1.60g/kg dosed administration group; Bavin Chinese herbaceous peony breast increases capsule 1.60,0.80, three dosed administration groups of 0.40g/kg.Be administered once every day, successive administration 5 days.After the last administration after 1 hour, each is organized all animals dimethylbenzene 0.03ml is applied to the Mice Auricle auris dextra causes swollenly, left ear is done normal control.After 2 hours, put to death animal, draw materials in the punching of auricle same area with the 9mm card punch, weigh respectively, heavily deducting left ear recast with auris dextra is the swelling level index.The results are shown in Table 3.
By table 3 result as seen, RUKANG PIAN and bavin Chinese herbaceous peony breast increase capsule 1.60, the 0.80g/kg xylol causes the swelling of Mice Auricle inflammation the obvious suppression effect.
1.4, to the outgrowth influence of mice filter paper granuloma:
Get 60 mices, be divided into 5 groups at random.The blank group; RUKANG PIAN 1.60g/kg dosed administration group; Bavin Chinese herbaceous peony breast increases capsule 1.60,0.80, three dosed administration groups of 0.40g/kg.The mouse web portion routine disinfection is done a little otch that is about 0.3cm in the abdominal part median line, implants the 4mg filter paper of sterilizing subcutaneous, sew up the incision, routine disinfection, postoperative began administration the same day, and be administered once every day, successive administration 8 days, hara kiri skin was peeled off and is taken out filter paper and granuloma with mice execution in the 9th day, place 80 ℃ of oven dryings to take out after one hour and weigh, the weight that deducts former filter paper is granulomatous weight.The results are shown in Table 4.
By table 4 result as seen, RUKANG PIAN and bavin Chinese herbaceous peony breast increase capsule 1.60,0.80g/kg causes the mice granulation hyperplasia that the obvious suppression effect is arranged to the mice filter paper.
1.5, to the influence of mouse peritoneal capillary permeability:
Get 60 mices, be divided into 5 groups at random.The blank group; RUKANG PIAN 1.60g/kg dosed administration group; Bavin Chinese herbaceous peony breast increases capsule 1.60,0.80, three dosed administration groups of 0.40g/kg.Be administered once every day, successive administration 5 days.After the last administration 1 hour in mouse tail vein injection 1% Yi Wensilan 0.1ml/10g body weight, lumbar injection 0.7% acetic acid 0.1ml/10g body weight immediately, put to death mice after 20 minutes, with 2ml normal saline flushing abdominal cavity, extract 1.6ml peritoneal irrigation liquid and add normal saline 5ml so far, centrifugal, with 752 type spectrophotometers in 590nm place colorimetric.The results are shown in Table 5.
By table 5 result as seen, RUKANG PIAN and bavin Chinese herbaceous peony breast increase capsule 1.60, the 0.80g/kg Dichlorodiphenyl Acetate causes the mouse peritoneal capillary permeability to strengthen the obvious suppression effect.
2. analgesic activity:
2.1, to the influence of mice hot plate zest pain:
Screen 55 of qualified female mices with hot plate dolorimeter 1 (MGJ-8402 type, 55 ± 0.5 ℃), be divided into 5 groups at random.The blank group; RUKANG PIAN 1.60g/kg dosed administration group; Bavin Chinese herbaceous peony breast increases capsule 1.60,0.80, three dosed administration groups of 0.40g/kg.Be administered once every day, successive administration 5 days.Measure the mice pain threshold in 1,2,3,4,5 hour after the last administration, the results are shown in Table 6.
By table 6 result as seen, RUKANG PIAN and bavin Chinese herbaceous peony breast increase capsule hot plate are caused that mice pain has significant analgesia role, and bavin Chinese herbaceous peony breast increases sustainable 5 hours of action time of capsule 1.60g/kg dosed administration group.
2.2, the influence of Dichlorodiphenyl Acetate induced mice pain:
Get 60 mices, be divided into 5 groups at random.The blank group; RUKANG PIAN 1.60g/kg dosed administration group; Bavin Chinese herbaceous peony breast increases capsule 1.60,0.80, three dosed administration groups of 0.40g/kg.Be administered once every day, successive administration 5 days.The interior mouse writhing reaction times of 10min behind each Mus ip0.7% acetic acid 10ml/kg observation in 0.5 hour and the record 5min after the last administration.The results are shown in Table 7.
By table 7 result as seen, RUKANG PIAN and bavin Chinese herbaceous peony breast increase capsule 1.60,0.80g/kg group Dichlorodiphenyl Acetate causes the mouse writhing reaction times to increase the obvious suppression effect.
3, blood circulation promoting and blood stasis dispelling experiment
3.1, to the influence of rat thrombus in vivo:
Get 50 of rats, be divided into 5 groups at random.The blank group; RUKANG PIAN 1.12g/kg dosed administration group; Bavin Chinese herbaceous peony breast increases capsule 1.12,0.56, three dosed administration groups of 0.28g/kg.Be administered once every day, successive administration 5 days.Back of the body position was fixing, separated right carotid in animal lumbar injection 300mg/kg chloral hydrate anesthesia in 1 hour after the last administration, form analyzer with experimental thrombus in vivo, far-end is put thermal detector, behind 2.0mA galvanic stimulation 3min, write down its duration of congestion, i.e. thrombus formation time.The results are shown in Table 8.
By table 8 result as seen, RUKANG PIAN and bavin Chinese herbaceous peony breast increase capsule 1.12, the 0.56g/kg group is formed with the obvious suppression effect to the rat thrombus in vivo.
3.2, to the thrombotic influence of blood stasis model rats in vitro:
Get 48 of rats, be divided into 6 groups at random.The blank group; The blood stasis model group; RUKANG PIAN 1.12g/kg dosed administration group; Bavin Chinese herbaceous peony breast increases capsule 1.12,0.56, three dosed administration groups of 0.28g/kg.Be administered once every day, successive administration 5 days, in administration the 2nd, the 3rd day except that the blank group all the other each groups subcutaneous injection 0.1% adrenalin hydrochlorides (Adr) 0.1ml/ are only respectively
[7], respectively rat is placed 1.5 ℃ of frozen water 5min that swims behind the 30min, only injecting Adr on the 4th day does not carry out ice bath, prepares blood stasis model with this.The blood sampling of abdomen cardinal vein was observed external thrombus and is formed situation on extracorporeal thrombosis forming device, be index with thrombosis length, weight in wet base, dry weight in each treated animal lumbar injection 300mg/kg chloral hydrate anesthesia in 1 hour after the last administration.The results are shown in Table 9.
By table 9 result as seen, bavin Chinese herbaceous peony breast increases capsule 1.12, two dosed administration groups of 0.56g/kg can obviously suppress rats in vitro thrombosis, thrombosis length and thrombus weight.
3.3, to the influence of clotting time of mice:
Get 60 mices, be divided into 5 groups at random.The blank group; RUKANG PIAN 1.60g/kg dosed administration group; Bavin Chinese herbaceous peony breast increases capsule 1.60,0.80, three dosed administration groups of 0.40g/kg.Be administered once every day, successive administration 5 days.After the last administration 1 hour by mice socket of the eye venous blood collection, survey clotting time with slide method.The results are shown in Table 10.
By table 10 result as seen, RUKANG PIAN and bavin Chinese herbaceous peony breast increase capsule 1.60, the 0.80g/kg group can obviously prolong the clotting time of mice.
4, bavin Chinese herbaceous peony breast increases capsule to the outgrowth influence of rat mammary gland
(1) medicine and reagent
Bavin Chinese herbaceous peony breast increases capsule, and the Jilin Prov. Inst. of Chinese Medicine and Chinese Medical Science provides.Lot number: 040301, the patent medicine specification: the 0.4g/ grain is made into desired concn for gastric infusion with distilled water during experiment.The positive drug RUKANG PIAN, Ankang Chia Tai Pharmaceutical Co., Ltd. provides.Lot number: 040102, the patent medicine specification: the 0.35g/ sheet is made into desired concn for gastric infusion with distilled water during experiment.Estradiol benzoate injection is Shanghai General Pharmaceutical Co., ltd., lot number: 050105; Progesterone injection is a Zhejiang Province XianJu Pharmacy stock Co., Ltd, lot number: 050803.Estradiol (Estradiol, E :), (Progestin, P) radioimmunological kit is available from the Fu Rui of Beijing bio-engineering corporation for progesterone.
(2) method and result
Get 60 of rats, be divided into 6 groups at random.The blank group; The hyperplasia of mammary gland model group; RUKANG PIAN 1.12g/kg dosed administration group; Bavin Chinese herbaceous peony breast increases capsule 1.12,0.56, three dosed administration groups of 0.28g/kg.Except that the blank group, each group is used estradiol benzoate 0.5mg/kg intramuscular injection 25 days, uses progesterone injection 4mg/kg intramuscular injection 5 days again instead, preparation rat mammary gland hypertrophy disease model.Be administered once every day simultaneously at the injection estradiol benzoate injection, successive administration 30 days was got blood, serum measured by radioimmunoassay E2 and P concentration in 24 hours behind last injection progesterone injection; The results are shown in Table 11.The 2nd pair of breast of clip chest, slide gauge are accurately measured papilla diameter, highly; The results are shown in Table 12.Again breast is immersed in 10% formalin solution fixing, under the mirror to mammary gland acinus, conduit and between the hyperplasia degree of matter mark respectively, 3 accumulated values of marking are the cyclomastopathy degree, and calculate the cyclomastopathy rate.Normally: (one), 1 minute; Slight hypertrophy: (+), 2 minutes; Moderate hypertrophy: (++), 3 minutes; The severe hypertrophy: (+++), 4 minutes.The results are shown in Table 13.
By table 11 result as seen, the rat mammary gland model of hyperplasia of estradiol benzoate and Progesterone preparation can make E2 rising in the rat blood serum, the imbalance of E2/P ratio; And bavin Chinese herbaceous peony breast increases capsule and can suppress obviously in the rat blood serum that E2 raises, the imbalance of E2/P ratio, and 1.12g/kg dosed administration group effect is best.
By table 12 result as seen, the rat mammary gland model of hyperplasia of estradiol benzoate and Progesterone preparation can make rat papilla diameter and height of nipples increase, and bavin Chinese herbaceous peony breast increases the increase that capsule can obviously suppress cyclomastopathy rat papilla diameter and height of nipples.
By table 13 result as seen, the rat mammary gland model of hyperplasia of estradiol benzoate and Progesterone preparation can make the rat mammary gland hypertrophy, and bavin Chinese herbaceous peony breast increases the cyclomastopathy that capsule can obviously suppress the cyclomastopathy rat.
Experiment conclusion
Pharmacodynamic experiment is the result show, bavin Chinese herbaceous peony breast increases capsule has obvious inhibitory action to the cyclomastopathy of cyclomastopathy rat; Bavin Chinese herbaceous peony breast increases the rat paw edema that the capsule on Carrageenan causes obvious inhibitory action, can obviously suppress the swelling of mice caused by dimethylbenzene xylene auricle inflammation, cause swelling of rat granulation and filter paper to cause the mice granulation hyperplasia that the obvious suppression effect is arranged to cotton balls, the mouse peritoneal capillary permeability that Dichlorodiphenyl Acetate causes strengthens obvious inhibitory action, illustrates that bavin Chinese herbaceous peony breast increases capsule tangible antiinflammatory action is arranged; Bavin Chinese herbaceous peony breast increases capsule hot plate is caused that mice pain has significant analgesia role, and the mouse writhing increased frequency that Dichlorodiphenyl Acetate causes has the obvious suppression effect, illustrates that bavin Chinese herbaceous peony breast increases capsule significant analgesia role is arranged.Bavin Chinese herbaceous peony breast increases capsule can obviously suppress rat vivo and vitro thrombosis, prolongs clotting time, illustrates that this medicine has tangible function of promoting blood circulation to disperse blood clots.
In sum, experimental results show that more than drug prepared bavin Chinese herbaceous peony breast of the present invention increases capsule and provides full and accurate experimental basis at gynaecopathias such as treatment cyclomastopathy.
Acute toxicity testing is the result show, limits because of administration concentration and volume, fails to measure the LD that bavin Chinese herbaceous peony breast increases the capsule gastric infusion
50Animal is in good condition after the administration, body weight gain is normal, breathing, activity, diet, defecation are all normal, mouth, eye, the no abnormal secretions of nose, no any abnormal response in 14 days, and none animal dead, the maximum dosage-feeding that records gastric infusion in its 24 hours is 40g/kg, 583.3 times of quite clinical consumption.
Long term toxicity test is the result show, bavin Chinese herbaceous peony breast increases capsule and gives rat oral gavage administration 180 days with 8.0-2.0g/kg dosage, growth of animal state, movable diet, hematology, blood biochemical, organ index and organs and tissues structure all there is not obvious influence, wherein bavin Chinese herbaceous peony breast increases capsule with 8.0g/kg, 116.7 times of quite clinical consumption.
Four, the specific embodiment
The preparation method of embodiment 1 medicinal tablet of the present invention is to count ratio by following crude drug to make:
Radix Bupleuri 150 grams, Radix Curcumae 150 grams, Radix Paeoniae Rubra 150 grams, Spica Prunellae 235 grams, Rhizoma Cyperi 150 grams, Colla cornus cervi 75 grams, Semen Citri Reticulatae 150 grams, Radix Scrophulariae 235 grams, Bulbus Fritillariae Thunbergii 75 grams, Sargassum 150 grams.
Preparation method is:
1) above ten flavors, Colla cornus cervi and Bulbus Fritillariae Thunbergii are ground into fine powder, and Radix Paeoniae Rubra is with 80% alcohol reflux 3 times, and each 1.0 hours, alcohol adding amount was 6 times, merge extractive liquid,, filtration, filtrate recycling ethanol also is evaporated to the thick paste of relative density 1.30～1.35 (80 ℃); Medicinal residues and Radix Bupleuri, Radix Curcumae, Spica Prunellae, Rhizoma Cyperi, Semen Citri Reticulatae, Radix Scrophulariae, Sargassum merge, adding 8 times of medical material water gagings decocts 3 times, each 1.5 hours, collecting decoction filtered, filtrate decompression is concentrated into the clear paste of relative density 1.10～1.15 (80 ℃), add ethanol and make determining alcohol reach 50%, fully stir static 24 hours, filter, filtrate recycling ethanol also is evaporated to the thick paste of relative density 1.30～1.35 (80 ℃); Thick paste and Radix Paeoniae Rubra alcohol extract merge, and add Colla cornus cervi and Bulbus Fritillariae Thunbergii fine powder, and 80 ℃ of drying under reduced pressure are ground into fine powder.
2) adjuvant of the conventional film-making agent of adding, tabletting.
The preparation of embodiment 2 medicine capsules of the present invention
It is made by following crude drug:
Radix Bupleuri 170 grams, Radix Curcumae 170 grams, Radix Paeoniae Rubra 170 grams, Spica Prunellae 255 grams, Rhizoma Cyperi 170 grams, Colla cornus cervi 85 grams, Semen Citri Reticulatae 170 grams, Radix Scrophulariae 255 grams, Bulbus Fritillariae Thunbergii 85 grams, Sargassum 170 grams.
Preparation method comprises: step 1) is with embodiment 1;
2) incapsulate.
The preparation of embodiment 3 medicinal granules of the present invention
It is made by following crude drug:
Radix Bupleuri 190 grams, Radix Curcumae 190 grams, Radix Paeoniae Rubra 190 grams, Spica Prunellae 275 grams, Rhizoma Cyperi 190 grams, Colla cornus cervi 95 grams, Semen Citri Reticulatae 190 grams, Radix Scrophulariae 275 grams, Bulbus Fritillariae Thunbergii 95 grams, Sargassum 190 grams;
Preparation method comprises: step 1) is with embodiment 1;
2) add starch, granulate drying.
Table 2. bavin Chinese herbaceous peony breast increases capsule to the granulomatous influence of rat (X ± s)
| Group | Mus number (only) | Granulation weight (mg) |
| Matched group | 10 | 111.30±3.86 |
| RUKANG PIAN 1.12g/kg | 10 | 94.90±5.55 ※ |
| Bavin Chinese herbaceous peony breast increases capsule 1.12g/kg | 10 | 80.40±4.74 ※※※ |
| Bavin Chinese herbaceous peony breast increases capsule 0.56g/kg | 10 | 96.80±6.14 ※ |
| Bavin Chinese herbaceous peony breast increases capsule 0.28g/kg | 10 | 101.80±5.43 |
Table 3. bavin Chinese herbaceous peony breast increases capsule to the influence of mice dimethylbenzene dropsy of ear (X ± s)
| Group | Mus number (only) | Two ear weight differences (mg) |
| Matched group | 12 | 15.17±3.74 |
| RUKANG PIAN 1.60g/kg | 12 | 10.75±3.44 ※ |
| Bavin Chinese herbaceous peony breast increases capsule 1.60g/kg | 12 | 8.67±3.45 ※※ |
| Bavin Chinese herbaceous peony breast increases capsule 0.80g/kg | 12 | 10.25±3.86 ※ |
| Bavin Chinese herbaceous peony breast increases capsule 0.40g/kg | 12 | 13.25±4.03 |
Table 4. bavin Chinese herbaceous peony breast increases capsule to the granulomatous influence of mice (X ± s)
| Group | Mus number (only) | Granulation weight (mg) |
| Matched group | 12 | 19.33±2.42 |
| RUKANG PIAN 1.60g/kg | 12 | 15.75±2.38 ※※ |
| Bavin Chinese herbaceous peony breast increases capsule 1.60g/kg | 12 | 13.83±1.85 ※※※ |
| Bavin Chinese herbaceous peony breast increases capsule 0.80g/kg | 12 | 16.33±2.02 ※※ |
| Bavin Chinese herbaceous peony breast increases capsule 0.40g/kg | 12 | 18.67±1.97 |
Table 5. bavin Chinese herbaceous peony breast increases capsule to the influence of mouse peritoneal capillary permeability (X ± s)
| Group | Mus number (only) | The OD value |
| Matched group | 12 | 0.74±0.077 |
| RUKANG PIAN 1.60g/kg | 12 | 0.54±0.179 ※※※ |
| Bavin Chinese herbaceous peony breast increases capsule 1.60g/kg | 12 | 0.53±0.130 ※※ |
| Bavin Chinese herbaceous peony breast increases capsule 0.80g/kg | 12 | 0.60±0.11 ※ |
| Bavin Chinese herbaceous peony breast increases capsule 0.40g/kg | 12 | 0.65±0.147 |
Table 7. bavin Chinese herbaceous peony breast increases the influence that the capsule Dichlorodiphenyl Acetate brings out the mouse writhing reaction
| Group | Mus number (only) | Turn round body number of times (inferior) |
| Matched group | 12 | 18.42±4.89 |
| RUKANG PIAN 1.60g/kg | 12 | 7.75±3.60 ※※ |
| Bavin Chinese herbaceous peony breast increases capsule 1.60g/kg | 12 | 7.83±3.38 ※※※ |
| Bavin Chinese herbaceous peony breast increases capsule 0.80g/kg | 12 | 9.42±3.84 ※※ |
| Bavin Chinese herbaceous peony breast increases capsule 0.40g/kg | 12 | 10.67±5.19 |
Table 8. bavin Chinese herbaceous peony breast increases the influence of capsule to the rat thrombus in vivo
| Group | Mus number (only) | Thrombus formation time (branch) |
| Matched group | 10 | 7.32±1.11 |
| RUKANG PIAN 1.12g/kg | 10 | 8.78±1.07 ※ |
| Bavin Chinese herbaceous peony breast increases capsule 1.12g/kg | 10 | 9.80±1.09 ※※※ |
| Bavin Chinese herbaceous peony breast increases capsule 0.56g/kg | 10 | 8.47±0.97 ※※ |
| Bavin Chinese herbaceous peony breast increases capsule 0.28g/kg | 10 | 7.82±0.91 |
Table 10. bavin Chinese herbaceous peony breast increases the influence of capsule to clotting time of mice
| Group | Mus number (only) | Clotting time (branch) |
| Matched group | 12 | 3.23±0.70 |
| RUKANG PIAN 1.60g/kg | 12 | 4.28±0.76 ※※ |
| Bavin Chinese herbaceous peony breast increases capsule 1.60g/kg | 12 | 4.73±0.76 ※※※ |
| Bavin Chinese herbaceous peony breast increases capsule 0.80g/kg | 12 | 4.17±0.66 ※※ |
| Bavin Chinese herbaceous peony breast increases capsule 0.40g/kg | 12 | 3.68±0.63 |
Claims (4)
1. medicine for the treatment of cyclomastopathy is characterized in that this medicine is the medicament of being made by the raw material of following ratio of weight and number:
150～190 parts of 150～190 parts of Radix Paeoniae Rubra of 150～190 portions of Radix Curcumaes of Radix Bupleuri
75～95 parts of 150～190 parts of Colla cornus cervis of 235～275 portions of Rhizoma Cyperis of Spica Prunellae
75～95 parts of 235～275 parts of Bulbus Fritillariae Thunbergiis of 150～190 portions of Radix Scrophulariaes of Semen Citri Reticulatae
150～190 parts of Sargassums.
2. a kind of medicine for the treatment of cyclomastopathy as claimed in claim 1 is characterized in that this medicine is the medicament of being made by the raw material of following ratio of weight and number:
170 parts of 170 parts of Radix Paeoniae Rubra of 170 portions of Radix Curcumaes of Radix Bupleuri
85 parts of 170 parts of Colla cornus cervis of 255 portions of Rhizoma Cyperis of Spica Prunellae
85 parts of 255 parts of Bulbus Fritillariae Thunbergiis of 170 portions of Radix Scrophulariaes of Semen Citri Reticulatae
170 parts of Sargassums.
3. a kind of medicine for the treatment of cyclomastopathy as claimed in claim 1 or 2 is characterized in that: comparing the dosage form of being manufactured with above-mentioned material component number is acceptable clinically all oral medicinal herb preparations.
4. a kind of preparation method for the treatment of the medicine of cyclomastopathy described in the production claim 3 is characterized in that:
More than ten the flavor, Colla cornus cervi and Bulbus Fritillariae Thunbergii are ground into fine powder; Radix Paeoniae Rubra is with 80% alcohol reflux 3 times, and each 1.0 hours, alcohol adding amount was 6 times, and merge extractive liquid, filters, and filtrate recycling ethanol is also surveyed the thick paste of relative density 1.30～1.35 when being evaporated to 80 ℃; Radix Paeoniae Rubra medicinal residues and Radix Bupleuri, Radix Curcumae, Spica Prunellae, Rhizoma Cyperi, Semen Citri Reticulatae, Radix Scrophulariae, Sargassum merge, adding 8 times of medical material water gagings decocts 3 times, each 1.5 hours, collecting decoction filtered, when being concentrated into 80 ℃, filtrate decompression surveys the clear paste of relative density 1.10～1.15, add ethanol and make determining alcohol reach 50%, fully stir static 24 hours, filter, filtrate recycling ethanol is also surveyed the thick paste of relative density 1.30～1.35 when being evaporated to 80 ℃; Thick paste and Radix Paeoniae Rubra alcohol extract thick paste merge, and add Colla cornus cervi and Bulbus Fritillariae Thunbergii fine powder, and 80 ℃ of drying under reduced pressure are ground into fine powder, make the suitable for oral administration dosage form.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008100179980A CN101559196B (en) | 2008-04-18 | 2008-04-18 | Medicament for treating the hyperplasia of mammary glands and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008100179980A CN101559196B (en) | 2008-04-18 | 2008-04-18 | Medicament for treating the hyperplasia of mammary glands and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101559196A CN101559196A (en) | 2009-10-21 |
| CN101559196B true CN101559196B (en) | 2011-09-07 |
Family
ID=41218288
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008100179980A Active CN101559196B (en) | 2008-04-18 | 2008-04-18 | Medicament for treating the hyperplasia of mammary glands and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101559196B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102626502A (en) * | 2011-11-07 | 2012-08-08 | 仲崇琳 | Traditional Chinese medicinal composition for treating mammary gland hyperplasia |
| CN109078154A (en) * | 2018-10-31 | 2018-12-25 | 中山市六安堂健康管理有限公司 | A kind of pharmaceutical composition and its preparation method and application for treating the proliferation of mammary gland |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1539432A (en) * | 2003-04-24 | 2004-10-27 | 刘连华 | Granule of intermal dissolution for breast nodule |
| CN1857670A (en) * | 2006-03-21 | 2006-11-08 | 吉林省中医中药研究院 | Medicine for treating hyperplasia of mammary glands and its preparing method |
-
2008
- 2008-04-18 CN CN2008100179980A patent/CN101559196B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1539432A (en) * | 2003-04-24 | 2004-10-27 | 刘连华 | Granule of intermal dissolution for breast nodule |
| CN1857670A (en) * | 2006-03-21 | 2006-11-08 | 吉林省中医中药研究院 | Medicine for treating hyperplasia of mammary glands and its preparing method |
Non-Patent Citations (2)
| Title |
|---|
| 周家萍.中医治疗乳腺增生病近况.《广西中医药》.2005,第28卷(第2期),7-9. * |
| 芦锰.乳腺增生病的中医药治疗概况.《河南中医学院学报》.2007,(第2期),83-85. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101559196A (en) | 2009-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103751310B (en) | A kind of traditional Chinese medicine for external application and its preparation method treating fascitis | |
| CN103169928B (en) | Externally applied traditional Chinese medicine composition for treating dysmenorrhea, as well as preparation method and application thereof | |
| CN101002912A (en) | Method for preparing Yueshu dripping pills to treat dysmenorrhea | |
| CN105998334A (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating haemorrhoids | |
| CN101095923B (en) | Chinese traditional medicine for treating ectopic pregnancy | |
| CN103341092B (en) | Preparation method of powder for treating atrophic vaginitis | |
| CN102908579B (en) | Traditional Chinese medicine preparation for treating gynecological diseases, liver diseases and prostatitis and preparation method of traditional Chinese medicine preparation | |
| CN104524071A (en) | Pharmaceutical composition for treating primary renal disease and application thereof | |
| CN101559196B (en) | Medicament for treating the hyperplasia of mammary glands and preparation method thereof | |
| CN101607067B (en) | Traditional Chinese medicine preparation for treating cholelithiasis and preparation method thereof | |
| CN103285284B (en) | Medical composition for treating senile vaginitis | |
| CN103301353B (en) | Pharmaceutical composition for treating atrophic vaginitis | |
| CN102626502A (en) | Traditional Chinese medicinal composition for treating mammary gland hyperplasia | |
| CN104784538A (en) | Chinese medicinal preparation for treating diabetes and preparation method | |
| CN103301365A (en) | Cataplasm for treating cervical spondylosis and preparation method thereof | |
| CN100453099C (en) | Lefukang preparation and its preparing process | |
| CN103330867B (en) | Preparation method of powder for treating senile vaginitis | |
| CN103520329A (en) | Traditional Chinese medicine prescription used for treating prostatic cancer | |
| CN103316270B (en) | Preparation method of powder of medicine for treating postnatal perineum mucosal lesion | |
| CN108514631A (en) | A kind of drug and preparation method thereof for treating cardiac neurosis | |
| CN103330896B (en) | Preparation method of powder for treating postpartum nonspecific vaginitis | |
| CN115245549B (en) | Traditional Chinese medicine composition for improving gouty arthritis with damp-heat constitution | |
| CN100408085C (en) | Snow lotus preparation for treating prostate disease | |
| CN105477264A (en) | Medicinal preparation for treating urethral syndrome | |
| CN106806680A (en) | Raw white side's prepared slices of Chinese crude drugs combination preparation, preparation method and assembly packaging |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20091021 Assignee: XI AN TIANJIAN Research Institute OF MED Assignor: Wang Jie Contract record no.: 2013610000054 Denomination of invention: Medicine for treating hyperplasia of mammary glands and its preparing method Granted publication date: 20110907 License type: Exclusive License Record date: 20130522 |
|
| LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Medicine for treating hyperplasia of mammary glands and its preparing method Effective date of registration: 20160107 Granted publication date: 20110907 Pledgee: Xianyang financing Company Limited by Guarantee Pledgor: Wang Jie|XI AN TIANJIAN Research Institute OF MED Registration number: 2015990001209 |
|
| PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20160729 Granted publication date: 20110907 Pledgee: Xianyang financing guarantee Limited by Share Ltd. Pledgor: Wang Jie|XI AN TIANJIAN Research Institute OF MED Registration number: 2015990001209 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Medicine for treating hyperplasia of mammary glands and its preparing method Effective date of registration: 20160729 Granted publication date: 20110907 Pledgee: Xianyang financing guarantee Limited by Share Ltd. Pledgor: Wang Jie|XI AN TIANJIAN Research Institute OF MED Registration number: 2016990000644 |
|
| PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
| PM01 | Change of the registration of the contract for pledge of patent right |
Change date: 20160729 Registration number: 2015990001209 Pledgee after: Xianyang financing guarantee Limited by Share Ltd. Pledgee before: Xianyang financing Company Limited by Guarantee |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20161215 Granted publication date: 20110907 Pledgee: Xianyang financing guarantee Limited by Share Ltd. Pledgor: Wang Jie|XI AN TIANJIAN Research Institute OF MED Registration number: 2016990000644 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Medicine for treating hyperplasia of mammary glands and its preparing method Effective date of registration: 20161223 Granted publication date: 20110907 Pledgee: Xianyang financing guarantee Limited by Share Ltd. Pledgor: Wang Jie|XI AN TIANJIAN Research Institute OF MED Registration number: 2016990001162 |
|
| PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20171221 Granted publication date: 20110907 Pledgee: Xianyang financing guarantee Limited by Share Ltd. Pledgor: Wang Jie|XI AN TIANJIAN Research Institute OF MED Registration number: 2016990001162 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Medicine for treating hyperplasia of mammary glands and its preparing method Effective date of registration: 20180103 Granted publication date: 20110907 Pledgee: Xianyang financing guarantee Limited by Share Ltd. Pledgor: Wang Jie Registration number: 2018610000001 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20190115 Granted publication date: 20110907 Pledgee: Xianyang financing guarantee Limited by Share Ltd. Pledgor: Wang Jie Registration number: 2018610000001 |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20190619 Address after: 710116 7 Seats in Area A of Starfish Digital Workshop, West of Keyuan Third Road, North of Hongguang Avenue, Fengdong New Town, Xi'an City, Shaanxi Province Patentee after: XI AN TIANJIAN Research Institute OF MED Address before: 712000 4th Floor, Science and Technology Bureau, No. 6 Qinhuang Road, Xianyang City, Shaanxi Province Patentee before: Wang Jie |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Medicine for treating hyperplasia of mammary glands and its preparing method Effective date of registration: 20191113 Granted publication date: 20110907 Pledgee: Xi'an innovation financing Company limited by guarantee Pledgor: XI AN TIANJIAN Research Institute OF MED Registration number: Y2019990000523 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20220218 Granted publication date: 20110907 Pledgee: Xi'an innovation financing Company limited by guarantee Pledgor: XI AN TIANJIAN Research Institute OF MED Registration number: Y2019990000523 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: The invention relates to a drug for treating breast hyperplasia and a preparation method thereof Effective date of registration: 20220221 Granted publication date: 20110907 Pledgee: Xi'an innovation financing Company limited by guarantee Pledgor: XI AN TIANJIAN Research Institute OF MED Registration number: Y2022610000043 |
|
| CP03 | Change of name, title or address | ||
| CP03 | Change of name, title or address |
Address after: Block 7, Area A, Tianhaixing Digital Workshop, north of Hongguang Avenue, North of Hongguang Avenue, Xixian New District, Xixian New District, Shaanxi Province, 710075 Patentee after: Shaanxi Sanzheng Pharmaceutical Co.,Ltd. Address before: 710116 7 Seats in Area A of Starfish Digital Workshop, West of Keyuan Third Road, North of Hongguang Avenue, Fengdong New Town, Xi'an City, Shaanxi Province Patentee before: XI AN TIANJIAN Research Institute OF MED |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20231221 Granted publication date: 20110907 Pledgee: Xi'an innovation financing Company limited by guarantee Pledgor: XI AN TIANJIAN Research Institute OF MED Registration number: Y2022610000043 |